CARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione

DRUG3 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei Tumori, IRCCS Istituto Nazionale Tumori Fondazione Pascale

Conditions

AdvancedCARCINOMA OF THE ORAL CAVITY AND OROPHARYNXMerkel cell carcinomasnaïvenon-small cell lung cancer

Phase 2

Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial

RecruitingCTIS2022-502253-34-00

Fondazione IRCCS Istituto Nazionale Dei Tumorinon-small cell lung cancer

Start: 2023-09-11Target: 26Updated: 2023-05-02

Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial).

RecruitingCTIS2022-500988-12-00

Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei TumoriAdvanced, Merkel cell carcinomas, naïve

Start: 2023-12-18Target: 35Updated: 2024-05-24

Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial (ECT-HN)

CompletedCTIS2025-520735-16-00

IRCCS Istituto Nazionale Tumori Fondazione PascaleCARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

End: 2025-09-02Target: 96Updated: 2025-01-31